This early-stage study is testing an inhaled gene therapy called RCT1100 in adults with Primary Ciliary Dyskinesia (PCD) caused by specific DNAI1 gene mutations. The trial aims to see if the treatment improves mucus clearance from the lungs and is safe for participants. Researche…
Phase: PHASE1 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated Apr 02, 2026 03:42 UTC